Realizing the Promise of Cell and Gene Therapy with an Advanced Manufacturing Platform

As part of the Road to 50 States campaign, Inceptor Bio's Founder and CEO Shailesh Maingi and CSO Mike Nicholson speak to Nigel about the promise of cell and gene therapy, Inceptor's strategy and the new GMP manufacturing facility that will house the company's advanced manufacturing platform (AMP).

Shailesh Maingi

Shailesh Maingi is Founder/CEO of Kineticos Life Sciences, an award-winning life sciences advisory firm. In 2019, Shailesh launched the Kineticos Disruptor Fund, investing in life science start-ups. In 2020, he started Inceptor Bio, a biotech accelerator hub focused on advanced biological modalities such as gene therapy, cell therapy and gene editing. He cofounded the InVincible Cancer Research Fund in 2019. Shailesh serves on the Board of Directors for numerous biotechs and is Adjunct Faculty at UNC’s Kenan-Flagler School of Business.